Pirmenol

Pirmenol is an orally active antiarrhythmic agent. Pirmenol inhibits IK.ACh (IC50: 0.1 μM) by blocking mAchR. Pirmenol can be used in the research of cardiovascular disease, such as atrial fibrillation[1][2][4].

Product Specifications

CAS Number

[68252-19-7]

Product Name Alternative

(±) -Pirmenol; CI-845 (free base)

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

MAChR; Potassium Channel

Type

Reference compound

Related Pathways

GPCR/G Protein; Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/__plusmn__-Pirmenol.html

Solubility

10 mM in DMSO

Smiles

OC(C1=CC=CC=C1)(CCCN2[C@@H](C)CCC[C@H]2C)C3=CC=CC=N3

Molecular Formula

C22H30N2O

Molecular Weight

338.49

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P362+P364-P405-P501

References & Citations

[1]Watanabe Y, et al. Pirmenol inhibits muscarinic acetylcholine receptor-operated K+ current in the guinea pig heart. Eur J Pharmacol. 1997 Oct 29;338 (1) :71-4.|[2]Schardein JL, et al. Preclinical toxicology studies with a new antiarrhythmic agent: Pirmenol hydrochloride (CI-845) . Toxicol Appl Pharmacol. 1980 Nov;56 (2) :294-301.|[3]T Sawanobori, et al. Electrophysiologic and antiarrhythmic actions of pirmenol on rabbit and guinea pig cardiac preparations. J Cardiovasc Pharmacol. 1990 Dec;16 (6) :975-83. |[4]T E Mertz, et al. Pirmenol hydrochloride (CI-845) : antiarrhythmic profile in coronary artery ligated conscious dogs. J Cardiovasc Pharmacol. 1980 Sep-Oct;2 (5) :527-41.